Co-Diagnostics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Dwight Egan

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage	29.7%
CEO tenure	11yrs
CEO ownership	0.9%
Management average tenure	less than a year
Board average tenure	3.4yrs

Recent management updates

Recent updates

One Co-Diagnostics, Inc. (NASDAQ:CODX) Analyst Just Slashed Their Estimates By A Consequential 14%

May 18

A Look At The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Apr 14

Co-Diagnostics: Hold Thesis Remains Well Intact

Sep 07

Co-Diagnostics stock sinks ~37% after hours on Q2 results miss, hurt by lower volumes

Aug 11

Co-Diagnostics, Inc. (NASDAQ:CODX) Shares Could Be 29% Below Their Intrinsic Value Estimate

Mar 28

Co-Diagnostics: Swinging For The Fences

Jan 24

Does Co-Diagnostics (NASDAQ:CODX) Deserve A Spot On Your Watchlist?

Dec 28

Why Co-Diagnostics Is A Solid Covid-19 Play

Aug 19

Co-Diagnostics, Inc.'s (NASDAQ:CODX) Share Price Boosted 42% But Its Business Prospects Need A Lift Too

Aug 14

Co-Diagnostics gets CE marking for direct saliva SARS-CoV-2 test

Jun 18

Co-Diagnostics: No One-Hit Wonder

Jun 04

This Just In: Analysts Are Boosting Their Co-Diagnostics, Inc. (NASDAQ:CODX) Outlook for This Year

May 18

These Analysts Just Made A Huge Downgrade To Their Co-Diagnostics, Inc. (NASDAQ:CODX) EPS Forecasts

Mar 30

US$22.33: That's What Analysts Think Co-Diagnostics, Inc. (NASDAQ:CODX) Is Worth After Its Latest Results

Mar 27

CEO Compensation Analysis

How has Dwight Egan's remuneration changed compared to Co-Diagnostics's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$1m	US$375k	-US$35m
Sep 30 2023	n/a	n/a	-US$43m
Jun 30 2023	n/a	n/a	-US$38m
Mar 31 2023	n/a	n/a	-US$32m
Dec 31 2022	US$2m	US$366k	-US$14m
Sep 30 2022	n/a	n/a	US$15m
Jun 30 2022	n/a	n/a	US$28m
Mar 31 2022	n/a	n/a	US$40m
Dec 31 2021	US$2m	US$350k	US$37m
Sep 30 2021	n/a	n/a	US$42m
Jun 30 2021	n/a	n/a	US$46m
Mar 31 2021	n/a	n/a	US$51m
Dec 31 2020	US$1m	US$309k	US$42m
Sep 30 2020	n/a	n/a	US$28m
Jun 30 2020	n/a	n/a	US$10m
Mar 31 2020	n/a	n/a	-US$6m
Dec 31 2019	US$460k	US$275k	-US$6m
Sep 30 2019	n/a	n/a	-US$6m
Jun 30 2019	n/a	n/a	-US$6m
Mar 31 2019	n/a	n/a	-US$6m
Dec 31 2018	US$474k	US$275k	-US$6m
Sep 30 2018	n/a	n/a	-US$6m
Jun 30 2018	n/a	n/a	-US$8m
Mar 31 2018	n/a	n/a	-US$8m
Dec 31 2017	US$210k	US$195k	-US$7m

Compensation vs Market: Dwight's total compensation ($USD1.26M) is above average for companies of similar size in the US market ($USD677.87K).

Compensation vs Earnings: Dwight's compensation has been consistent with company performance over the past year.

CEO

Dwight Egan (70 yo)

11yrs

Tenure

US$1,261,300

Compensation

Mr. Dwight H. Egan serves as the Chairman & Chief Executive Officer and was President at Co-Diagnostics, Inc. and has been its Director since April 2013. Mr. Egan has been engaged in private investment bus...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Dwight Egan	Chairman & CEO	no data	US$1.26m	0.87% $ 311.5k
Brian Brown	CFO & Company Secretary	3.2yrs	US$1.04m	0.68% $ 245.2k
Richard Abbott	President	less than a year	no data	no data
Brent Satterfield	Co-Founder & Member of Scientific Advisory Board	11yrs	US$237.50k	no data
David Nielsen	Chief Operating Officer	no data	no data	no data
Dan Bohrer	Vice President of Finance & Accounting	no data	no data	no data
Christopher Thurston	Chief Technology Officer	no data	no data	no data
Mark Poritz	Chief Scientific Officer	1.4yrs	no data	no data
Andrew Benson	Head of Investor Relations	no data	no data	no data
Mayuranki Almaula	Senior Vice President of Overseas Operations & Strategic Alliances	no data	no data	no data
Cameron Gundry	Head of Commercialization LATAM/EUR	no data	no data	no data
Ivory Chang	Chief Regulatory Affairs Officer	less than a year	no data	no data

0.7yrs

Average Tenure

49yo

Average Age

Experienced Management: CODX's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Dwight Egan	Chairman & CEO	11yrs	US$1.26m	0.87% $ 311.5k
Brent Satterfield	Co-Founder & Member of Scientific Advisory Board	2.1yrs	US$237.50k	no data
Richard Serbin	Independent Director	6.9yrs	US$298.00k	0.28% $ 100.6k
Carl Wittwer	Chairman of Scientific Advisory Board	2.1yrs	no data	no data
James Nelson	Independent Director	4.7yrs	US$298.00k	0.27% $ 97.8k
Noriko Kusukawa	Member of Scientific Advisory Board	2.1yrs	no data	no data
Edward Murphy	Independent Director	4.8yrs	US$298.00k	0.31% $ 112.1k
Eugene Durenard	Independent Director	4.8yrs	US$298.00k	0.27% $ 97.8k
Karen Carroll	Member of Scientific Advisory Board	2.1yrs	no data	no data
Anne Wyllie	Member of Scientific Advisory Board	2.1yrs	no data	no data

3.4yrs

Average Tenure

58yo

Average Age

Experienced Board: CODX's board of directors are considered experienced (3.4 years average tenure).

Co-Diagnostics Management

Management criteria checks 2/4

Key information

Recent management updates

Co-Diagnostics, Inc. Appoints Executive Appointments

Chairman exercised options and sold US$58k worth of stock

Co-Diagnostics, Inc. Appoints Ivory Chang as Chief Regulatory Affairs Officer

Co-Diagnostics, Inc., Annual General Meeting, Aug 30, 2023

Chairman exercised options and sold US$111k worth of stock

High number of new and inexperienced directors

Recent updates

Co-Diagnostics, Inc. Appoints Executive Appointments

Full year 2023 earnings released

New major risk - Revenue and earnings growth

Co-Diagnostics, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro

Chairman exercised options and sold US$58k worth of stock

Consensus revenue estimates increase by 474%

Price target increased by 50% to US$3.00

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Co-Diagnostics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Co-Diagnostics, Inc. Appoints Ivory Chang as Chief Regulatory Affairs Officer

Consensus revenue estimates fall by 43%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Co-Diagnostics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Co-Diagnostics, Inc., Annual General Meeting, Aug 30, 2023

Co-Diagnostics, Inc. Receives Funding for Co-Dx PCR Home Platform from NIH RADx Tech Program

One Co-Diagnostics, Inc. (NASDAQ:CODX) Analyst Just Slashed Their Estimates By A Consequential 14%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Co-Diagnostics, Inc. to Report Q1, 2023 Results on May 11, 2023

A Look At The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Consensus revenue estimates fall by 83%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improves as stock rises 16%

Chairman exercised options and sold US$111k worth of stock

Consensus revenue estimates fall by 14%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Co-Diagnostics, Inc. Appoints Dr. Mark Poritz as New Chief Scientific Officer

Co-Diagnostics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Investor sentiment improved over the past week

Pomerantz Law Firm Announces the Filing of a Class Action Against Co-Diagnostics, Inc. and Certain Officers

Co-Diagnostics: Hold Thesis Remains Well Intact

Investor sentiment deteriorated over the past week

Kaplan Fox & Kilsheimer LLP Files Class Action Suit in the United States District Court for the Southern District of New York Against Co-Diagnostics, Inc

Price target decreased to US$15.33

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Co-Diagnostics stock sinks ~37% after hours on Q2 results miss, hurt by lower volumes

Co-Diagnostics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Co-Diagnostics, Inc., Annual General Meeting, Aug 31, 2022

Co-Diagnostics spikes on shipments of monkeypox test

Estimating The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Investor sentiment improved over the past week

Now 20% undervalued after recent price drop

Co-Diagnostics: Well Priced, Long-Term Value Remains Too Distant

Now 24% undervalued after recent price drop

Co-Diagnostics, Inc. Completes Principal Design of Test for Monkeypox Virus

Chairman exercised options and sold US$59k worth of stock

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorated over the past week

Price target decreased to US$19.33

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

Co-Diagnostics: Where's Eikon?

High number of new and inexperienced directors

Consensus EPS estimates increase by 36%

Co-Diagnostics, Inc. (NASDAQ:CODX) Shares Could Be 29% Below Their Intrinsic Value Estimate

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Co-Diagnostics: Swinging For The Fences

Investor sentiment deteriorated over the past week

Co-Diagnostics, Inc. (NasdaqCM:CODX) completed the acquisition of Advanced Conceptions, Inc.

Price target decreased to US$19.33

Does Co-Diagnostics (NASDAQ:CODX) Deserve A Spot On Your Watchlist?

Co-Diagnostics, Inc. (NasdaqCM:CODX) entered into an Agreement and Plan of Merger to acquire Idaho Molecular Inc.

Investor sentiment improved over the past week

Chairman exercised options and sold US$131k worth of stock

Third quarter 2021 earnings released: EPS US$0.40 (vs US$0.56 in 3Q 2020)

Co-Diagnostics, Inc. to Introduce at Home/Point of Care Device at AACC on Sept 28